OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

On October 17, 2024 OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, reported that Paul Romness, Chief Executive Officer, will be presenting at the 2024 Maxim Healthcare Virtual Summit (Press release, OS Therapies, OCT 17, 2024, View Source [SID1234647259]). The summit is being held virtually on October 15 – 17, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Date:

Thursday, October 17, 2024

Time:

3:00 PM ET

Webcast:

https://m-vest.com/events/healthcare-10152024

Breakpoint Therapeutics Announces Poster Presentation at the 36th EORTC-NCI-AACR Symposium

On October 17, 2024 Breakpoint Therapeutics GmbH ("Breakpoint"), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), reported that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024) (Press release, Breakpoint Therapeutics, OCT 17, 2024, View Source [SID1234647244]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DNA polymerase theta is a DNA repair enzyme that is largely absent in normal cells but displays aberrant expression in multiple cancer types which often correlates with poor prognosis. Inhibition of Pol θ is a validated therapeutic modality in certain tumour-specific contexts.

Details of the presentation are as follows:

Abstract Title: Discovery and characterisation of DNA polymerase theta inhibitors for the treatment of cancer

Date: Friday, 25 October, 2024

Time: 9:00 a.m. – 3:00 p.m. CEST

Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)

Abstract Number: 339

Poster Board Number: PB327

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

On October 17, 2024 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company’s investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC) (Press release, Zai Laboratory, OCT 17, 2024, View Source [SID1234647260]). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company’s website at View Source Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BI6f8ba8dc42d04cd3afd7095cf7c83d40

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website.

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

On October 17, 2024 Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of HEPZATO KIT (Press release, Delcath Systems, OCT 17, 2024, View Source [SID1234647246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement of the recording of $10.0 million in U.S. quarterly revenue from the commercialization of HEPZATO KIT effectively triggers the exercise of Tranche B warrants issued in the previously announced March 29, 2023 Private Investment in Public Equity (the "PIPE"). Holders of the Tranche B warrants from the PIPE have 21 days from the date of this announcement to exercise their Tranche B warrants to purchase shares of common stock at an effective price of $6.00 per share of common stock for an aggregate exercise price of up to approximately $25 million.

"This revenue milestone is an important indicator of the strong demand for HEPZATO KIT, highlighting the unmet medical need it addresses in uveal melanoma patients with liver metastases and the rapid uptake by physicians," said Gerard Michel, Chief Executive Officer of Delcath. "The Company will utilize the additional $25 million of financing to support the ongoing commercial launch and invest in new clinical trials to expand indications which we plan to initiate in 2025."

Final financial results for the third quarter and a detailed business update will be provided during Delcath’s quarterly financial results release and investor call scheduled for November 8, 2024.

Nusano and Starget Pharma Announce Supply Agreement to Accelerate Smart Targeted Radioligand Development

On October 17, 2024 Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide radioligand therapies focused on difficult to treat cancers, reported a supply agreement to advance the development of Starget’s Smart Targeted Radioligands (STRs) (Press release, Nusano, OCT 17, 2024, View Source [SID1234647247]). The supply agreement is expected to support Starget’s STR isotope needs from discovery through commercialization and will include both common radioisotopes as well as rare alpha particle-emitters such as Astatine-211, Lead-212, and Actinium-225.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to partner with Nusano, a leader in radioisotope production, to support the development of our novel pipeline of smart targeted radioligands," said Sigal Kalmanson Cusnir, CEO of Starget Pharma. "Our STR platform technology enables the rapid design and evaluation of radiotherapies in an isotope-agnostic manner, allowing us to optimize performance by tumor type. We are focused now on advancing our clinical pipeline, beginning with the planned initiation of a Phase 1b clinical trial in early 2025. The Nusano agreement will ensure that we have a reliable radioisotope supply chain, facilitating near and long term growth, with the ultimate goal of radically improving patient care and outcomes."

Starget’s STR platform is advancing the field of molecular radiation using its proprietary backbone cyclization technology to create innovative and diversified peptide radioligand candidates with enhanced properties. These STRs are designed to bind and deliver a payload of radiation specifically to biological targets that are overexpressed in cancer compared to normal cells. This highly focused radiation then damages the DNA in the cancer cells, leading to selective cell death and tumor shrinkage. Due to their unique molecular interaction with the target, STRs act with high sensitivity and precision, enabling effective radiation targeting tumors and metastasis.

Radioisotopes are essential components in the active pharmaceutical ingredients (API) used in new and emerging cancer therapies including molecular radiation. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development.

Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to medical and industrial markets. Opening in 2025 in West Valley City, Utah, the Nusano production platform will be capable of generating more than 25 radioisotopes applicable to medical and industrial uses. It is anchored by a proprietary ion source technology which accelerates heavy particles (alphas and deuterons) to generate high volume, high quality (cGMP-grade) radioisotopes with unparalleled efficiency using eco-friendly methods. The result is one of the first significant advancements in radioisotope production in decades.

Chris Lowe, CEO of Nusano commented, "The Nusano platform will make medical radioisotopes available in varieties and volumes needed to broaden and accelerate radiotherapeutics development. We share Starget’s enthusiasm for finding the right isotope to target specific tumor types and look forward to working with them to advance more isotopes into clinical development for the betterment of cancer patients around the world."